Viewpoint News & Awards

Viewpoint wins SBIR funding from the NCI – NIH.

June 23, 2014, (Iowa City). Iowa City based Viewpoint Molecular Targeting, LLC has secured a $150,000 Phase I Small Business Innovation Research Grant from the National Cancer Institute (National Institutes of Health) to advance development of a new diagnostic and therapeutic for metastatic melanoma. The company will use the funding to determine the feasibility of receptor targeted diagnostics and therapeutics for metastatic melanoma.The SBIR research is focused on commercialization of a new class of theranostic agent that has great potential for diagnosis and therapy for metastatic melanoma.

See more: www.radiomedix.com

Contacts:

 Michael K Schultz PhDChief Science OfficerViewpoint Molecular Targeting, LLC

michael-schultz@viewpointmt.com

Phone: +1 (865) 356-1861